NOV 22, 2016 10:04 AM PST

Brain Tumors All Aglow

WRITTEN BY: Xuan Pham
In as much as 50 percent of operations to remove brain tumors, some cancerous bits are left behind and the cancer makes a most unwelcomed return. Now, researchers at the University of Pennsylvania say a technique that makes brain tumors fluoresce during surgery will enable more thorough removal and minimize tumor recurrence.


 
Each year, surgeons operate on over 15,000 patients to remove brain tumors. The extremely delicate nature of these operations already put patients at increased risks for complications. Furthermore, the success of the operation is drastically minimized when tumor tissues are left behind because the tumor margins are difficult to identify.
 
To circumvent cancer’s ability to camouflage itself among normal tissues, Penn researchers set out to make cancer as visible as possible to the surgeon. Specifically, they engineered a dye that collects mostly in the tumor tissues, making the cancer glow brightly as compared to the healthy tissues.
 
The dye agent is known as indocyanine green (ICG), and it is visualized with near infrared imaging light. "Fluorescent contrast agents take visualization to a whole new level," said John Lee, associate professor at the University of Pennsylvania’s School of Medicine. "It has the potential for real-time imaging, identification of disease, and most importantly, precise detection of the tumor's margins. With this, we know better where to cut."
 
The concept of making tumors glow is not new. Last month, doctors from Seattle Children’s Hospital used a chemical called BLZ-100 Tumor Paint to aid in the removal of a brain tumor in a 2-year-old. Of note, both techniques employ the use of the dye, indocyanine green.
 

In the current pilot study at Penn, researchers say their technique showed successful visual enhancement in 12 out of 15 tumors. Of those patients in which the fluorescence signal was strong, surgeons reported the glow was visible even under the dura.
 
"This technique, if approved by the FDA, may offer great promise to physicians and patients," Singhal said. "It's a strategy that could allow greater precision across many different cancer types, help with early detection, and hopefully better treatment success."
 
Additional sources: Perelman School of Medicine at the University of Pennsylvania
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 14, 2021
Clinical & Molecular DX
AI-Powered Imaging System Can Tell If a Patient Is Cancer-Free
APR 14, 2021
AI-Powered Imaging System Can Tell If a Patient Is Cancer-Free
A patient undergoes chemotherapy and radiation for rectal cancer. How do doctors know whether all the malignant tissue h ...
APR 16, 2021
Cancer
Ion pump delivers chemotherapy directly to brain tumors
APR 16, 2021
Ion pump delivers chemotherapy directly to brain tumors
New research published in Advanced Materials Technologies highlights a development in fighting glioblastoma. The study f ...
MAY 05, 2021
Cancer
Developing Therapies to Combat Drug-Resistant Cell States
MAY 05, 2021
Developing Therapies to Combat Drug-Resistant Cell States
Drug resistant tumors present challenges in cancer treatment A significant challenge in the treatment of cancers is the ...
MAY 15, 2021
Cancer
What does your polygenic risk score mean?
MAY 15, 2021
What does your polygenic risk score mean?
A study published in The American Journal of Clinical Nutrition recommends that people with a high polygenic risk score ...
MAY 21, 2021
Cancer
How to address low representation of Black Americans in cancer trials
MAY 21, 2021
How to address low representation of Black Americans in cancer trials
The Abramson Cancer Center at the University of Pennsylvania (ACC) has succeeded in more than doubling the enrollment of ...
JUN 16, 2021
Cancer
New drug attacks pancreatic tumors with mutant KRAS addiction
JUN 16, 2021
New drug attacks pancreatic tumors with mutant KRAS addiction
Pancreatic cancer is notoriously difficult to detect in early stages, which is why it is associated with a low survival ...
Loading Comments...